Discovery of Natural Anthraquinones As Potent Inhibitors Against Pancreatic Lipase: Structure-activity Relationships and Inhibitory Mechanism

Overview

Journal J Enzyme Inhib Med Chem

Specialty Biochemistry

Date 2024 Sep 3

PMID 39223707

Authors

Zi-Qiang Chen

Wen-Yao He

Si-Yuan Yang

Hong-Hong Ma

Jing Zhou

Hao Li

Ya-Di Zhu

Xing-Kai Qian

Li-Wei Zou

Affiliations

Soon will be listed here.

Abstract

Obesity is acknowledged as a significant risk factor for various metabolic diseases, and the inhibition of human pancreatic lipase (hPL) can impede lipid digestion and absorption, thereby offering potential benefits for obesity treatment. Anthraquinones is a kind of natural and synthetic compounds with wide application. In this study, the inhibitory effects of 31 anthraquinones on hPL were evaluated. The data shows that AQ7, AQ26, and AQ27 demonstrated significant inhibitory activity against hPL, and exhibited selectivity towards other known serine hydrolases. Then the structure-activity relationship between anthraquinones and hPL was further analysed. AQ7 was found to be a mixed inhibition of hPL through inhibition kinetics, while AQ26 and AQ27 were effective non-competitive inhibition of hPL. Molecular docking data revealed that AQ7, AQ26, and AQ27 all could associate with the site of hPL. Developing hPL inhibitors for obesity prevention and treatment could be simplified with this novel and promising lead compound.

References

Zhao Y, Qian X, Guan X, Song P, Song Y, He R . Discovery of natural alkaloids as potent and selective inhibitors against human carboxylesterase 2. Bioorg Chem. 2020; 105:104367. DOI: 10.1016/j.bioorg.2020.104367. View

Nowak-Perlak M, Ziolkowski P, Wozniak M . A promising natural anthraquinones mediated by photodynamic therapy for anti-cancer therapy. Phytomedicine. 2023; 119:155035. DOI: 10.1016/j.phymed.2023.155035. View

Piche M, Tchernof A, Despres J . Obesity Phenotypes, Diabetes, and Cardiovascular Diseases. Circ Res. 2020; 126(11):1477-1500. DOI: 10.1161/CIRCRESAHA.120.316101. View

Hou X, Qin X, Hou J, Tang H, Ge G . The potential of natural sources for pancreatic lipase inhibitors: a solution of the obesity crisis?. Expert Opin Drug Discov. 2022; 17(12):1295-1298. DOI: 10.1080/17460441.2023.2156499. View

Szatmary P, Grammatikopoulos T, Cai W, Huang W, Mukherjee R, Halloran C . Acute Pancreatitis: Diagnosis and Treatment. Drugs. 2022; 82(12):1251-1276. PMC: 9454414. DOI: 10.1007/s40265-022-01766-4. View

Zhang L, Zheng J, Ma M, Zhao Y, Song J, Chen X . Drug-guided screening for pancreatic lipase inhibitors in functional foods. Food Funct. 2021; 12(10):4644-4653. DOI: 10.1039/d0fo03366a. View

Yadav N, Paul A . Pancreatic lipase and its related proteins: where are we now?. Drug Discov Today. 2023; 29(1):103855. DOI: 10.1016/j.drudis.2023.103855. View

Huang H, Han M, Gu Q, Wang J, Zhao H, Zhai B . Identification of pancreatic lipase inhibitors from Eucommia ulmoides tea by affinity-ultrafiltration combined UPLC-Orbitrap MS and in vitro validation. Food Chem. 2023; 426:136630. DOI: 10.1016/j.foodchem.2023.136630. View

Lin X, Li H . Obesity: Epidemiology, Pathophysiology, and Therapeutics. Front Endocrinol (Lausanne). 2021; 12:706978. PMC: 8450866. DOI: 10.3389/fendo.2021.706978. View

10.

Lin K, Lin W, Su C, Hsu H, Lin C . Design, synthesis and antitumour evaluation of novel anthraquinone derivatives. Bioorg Chem. 2021; 107:104395. DOI: 10.1016/j.bioorg.2020.104395. View

11.

Sciacca C, Cardullo N, Pulvirenti L, Di Francesco A, Muccilli V . Evaluation of honokiol, magnolol and of a library of new nitrogenated neolignans as pancreatic lipase inhibitors. Bioorg Chem. 2023; 134:106455. DOI: 10.1016/j.bioorg.2023.106455. View

12.

Qian X, Zhang J, Song P, Zhao Y, Ma H, Jin Q . Discovery of pyrazolones as novel carboxylesterase 2 inhibitors that potently inhibit the adipogenesis in cells. Bioorg Med Chem. 2021; 40:116187. DOI: 10.1016/j.bmc.2021.116187. View

13.

Guo C, Liao W, Qiu R, Zhou D, Ni W, Yu C . Aurantio-obtusin improves obesity and insulin resistance induced by high-fat diet in obese mice. Phytother Res. 2020; 35(1):346-360. DOI: 10.1002/ptr.6805. View

14.

Miles J, Leiter L, Hollander P, Wadden T, Anderson J, Doyle M . Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002; 25(7):1123-8. DOI: 10.2337/diacare.25.7.1123. View

15.

Qin X, Hou X, Zhu G, Xiong Y, Song Y, Zhu L . Discovery and Characterization of the Naturally Occurring Inhibitors Against Human Pancreatic Lipase in . Front Nutr. 2022; 9:844195. PMC: 8914261. DOI: 10.3389/fnut.2022.844195. View

16.

Kumar A, Chauhan S . Pancreatic lipase inhibitors: The road voyaged and successes. Life Sci. 2021; 271:119115. DOI: 10.1016/j.lfs.2021.119115. View

17.

Bracke A, Van Elzen R, Van der Veken P, Augustyns K, De Meester I, Lambeir A . The development and validation of a combined kinetic fluorometric activity assay for fibroblast activation protein alpha and prolyl oligopeptidase in plasma. Clin Chim Acta. 2019; 495:154-160. DOI: 10.1016/j.cca.2019.04.063. View

18.

Yan X . Anthraquinone-fused enediynes: discovery, biosynthesis and development. Nat Prod Rep. 2021; 39(3):703-728. DOI: 10.1039/d1np00054c. View

19.

Rosenson R, Gaudet D, Ballantyne C, Baum S, Bergeron J, Kershaw E . Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med. 2023; 29(3):729-737. PMC: 10033404. DOI: 10.1038/s41591-023-02222-w. View

20.

Zhang J, Yang Y, Qian X, Song P, Zhao Y, Guan X . Design, Synthesis, and Structure-Activity Relationship Study of Pyrazolones as Potent Inhibitors of Pancreatic Lipase. ChemMedChem. 2021; 16(10):1600-1604. DOI: 10.1002/cmdc.202000850. View